{"id":7152,"date":"2025-05-29T10:23:13","date_gmt":"2025-05-29T07:23:13","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7152"},"modified":"2025-05-29T10:23:13","modified_gmt":"2025-05-29T07:23:13","slug":"icosapent-ethyl-benefits-regardless-of-baseline-ldl-c","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/icosapent-ethyl-benefits-regardless-of-baseline-ldl-c\/","title":{"rendered":"Icosapent Ethyl Benefits Regardless of Baseline LDL-c"},"content":{"rendered":"
Icosapent Ethyl Benefits Regardless of Baseline LDL-c<\/div>\n
Source: Journal of the American Heart Association. 2025 (Published).<\/div>\n
<\/div>\n
Key Points:<\/div>\n
1. Study Background:<\/span><\/div>\n
\u2022 The REDUCE-IT trial previously showed that icosapent ethyl reduces cardiovascular (CV) events in high-risk patients(i.e., those with established vascular disease or its equivalents) with elevated triglycerides and LDL-c \u2264100 mg\/dL who are on statins.<\/span><\/div>\n
\u2022 This secondary analysis explored whether baseline LDL-c level (<55 mg\/dL vs. \u226555 mg\/dL) impacts the treatment\u2019s benefit.<\/span><\/div>\n
2. Study Population and Design:<\/span><\/div>\n
\u2022 8179 patients with high CV risk, triglycerides 135\u2013499 mg\/dL, and LDL-c 41\u2013100 mg\/dL.<\/span><\/div>\n
\u2022 Randomized to icosapent ethyl 2 g BID vs. placebo.<\/span><\/div>\n
\u2022 1058 patients (12.9%) had LDL-c <55 mg\/dL, 7117 (87.1%) had LDL-c \u226555 mg\/dL.<\/span><\/div>\n
3. Primary Outcome:<\/span><\/div>\n
\u2022 Composite of CV death, nonfatal MI, stroke, revascularization, or unstable angina.<\/span><\/div>\n
\u2022 Icosapent ethyl reduced risk in both LDL-c subgroups:<\/span><\/div>\n
\u2022 LDL-c <55 mg\/dL: HR 0.66; ARR: 6.6%; NNT: 15; P=0.003<\/span><\/div>\n
\u2022 LDL-c \u226555 mg\/dL: HR 0.76; ARR: 4.5%; NNT: 22; P<0.0001<\/span><\/div>\n
\u2022 No interaction by LDL-c level (P=0.40), suggesting consistent benefit.<\/span><\/div>\n
4. Secondary Outcome (CV death, MI, or stroke):<\/span><\/div>\n
\u2022 LDL-c <55 mg\/dL: HR 0.55; ARR: 6.4%; NNT: 16; P=0.0007<\/span><\/div>\n
\u2022 LDL-c \u226555 mg\/dL: HR 0.76; ARR: 3.2%; NNT: 32; P<0.0001<\/span><\/div>\n
\u2022 Again, no significant interaction (P=0.11).<\/span><\/div>\n
5. Safety Findings:<\/span><\/div>\n
\u2022 Similar rates of serious adverse events (19.7% vs. 20.0%) and drug-related adverse events (12.6% vs. 12.2%) between groups.<\/span><\/div>\n
\u2022 Slightly higher atrial fibrillation\/flutter with icosapent ethyl (5.8% vs. 4.5%; P=0.008).<\/span><\/div>\n
\u2022 Trend toward increased serious bleeding (2.7% vs. 2.1%; P=0.06).<\/span><\/div>\n
\u2022 No significant differences by LDL-c levels.<\/span><\/div>\n
6. Conclusion:\u00a0 the study supports the following clinical principle: \u201cTreat elevated hypertriglyceridemia in high-risk patients regardless of baseline LDL-c levels.<\/span><\/div>\n
\u2022 Icosapent ethyl significantly reduces CV events in statin-treated patients at high CV risk\u00a0 with elevated triglycerides, regardless of baseline LDL-c levels.<\/span><\/div>\n
\u2022 Patients with optimal LDL-c (<55 mg\/dL) still benefit substantially.<\/span><\/div>\n
https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.124.038656<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Icosapent Ethyl Benefits Regardless of Baseline LDL-c Source: Journal of the American Heart Association. 2025 (Published). Key Points: 1. Study Background: \u2022 The REDUCE-IT trial previously showed that icosapent ethyl reduces cardiovascular (CV) events in high-risk patients(i.e., those with established vascular disease or its equivalents) with elevated triglycerides and LDL-c \u2264100 mg\/dL who are on […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7152","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7152"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7152\/revisions"}],"predecessor-version":[{"id":7157,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7152\/revisions\/7157"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}